Australia ends Covid-19 vaccine trials due to HIV antibody positives

Following consultation with the Australian Government, UQ and CSL decided not to progress the vaccine candidate to phase 2 and 3 clinical trials.
The vaccine was one of four candidates that Australia had committed to buy and accordingly agreements were made to secure 51 million doses of the experimental vaccine.(REUTERS)
The vaccine was one of four candidates that Australia had committed to buy and accordingly agreements were made to secure 51 million doses of the experimental vaccine.(REUTERS)
Published on Dec 11, 2020 01:31 PM IST
Copy Link
Melbourne | ByPress Trust of India| Posted by Susmita Pakrasi

Australia on Friday stopped the further development of a Covid-19 vaccine candidate as several participants in the early-stage trials generated antibodies for HIV after receiving the potential therapeutic.

There were no serious adverse events or safety concerns reported in the 216 participants of the phase 1 trial of the v451 Covid-19 vaccine candidate being developed by the University of Queensland (UQ) in collaboration with biotech company CSL, according to a statement.

However, data showed that some patients developed antibodies towards fragments of a HIV protein (gp41), which was used to stabilise the vaccine, it said.

Following consultation with the Australian Government, UQ and CSL decided not to progress the vaccine candidate to phase 2 and 3 clinical trials.

The vaccine was one of four candidates that Australia had committed to buy and accordingly agreements were made to secure 51 million doses of the experimental vaccine.

UQ said the trial participants were fully informed of the possibility of a partial immune response to this protein component, however, it was unexpected that the antibody levels induced would interfere with certain HIV tests.

The university said there is no possibility the vaccine causes infection, and routine follow up tests confirmed there is no HIV virus present.

The decision was taken after the makers consulted experts who worked out the “implications” that this issue presents to rolling out the vaccine into broad populations, it said.

Reacting to the announcement, Australian Prime Minister Scott Morrison said abandoning the trial should show Australians the Government and researchers were proceeding carefully.

“What happened today is not a surprise to the Government. We are moving swiftly but not with any undue haste,” he said, adding the system’s working as it should and Australians are protected, as always.

The University of Queensland commenced the phase 1 trial of v451 in July 2020, to assess its safety and immunogenicity in healthy volunteers.

It said the vaccine candidate has shown that it elicits a robust response towards the novel coronavirus and has a strong safety profile.

However, significant changes would need to be made to well-established HIV testing procedures in the healthcare setting to accommodate rollout of this vaccine, according to the statement.

Although the makers have abandoned further trials, the university said the phase 1 trial will continue to assess how long the HIV antibodies persist, adding studies so far show that the levels are already falling.

The University of Queensland also plans to submit the full data for peer review publication.

UQ vaccine co-lead, Professor Paul Young, said that although it was possible to re-engineer the vaccine, the team did not have the luxury of time needed.

“Doing so would set back development by another 12 or so months, and while this is a tough decision to take, the urgent need for a vaccine has to be everyone’s priority,” Young said.

“I said at the start of vaccine development that there were no guarantees, but what is really encouraging is that the core technology approach we used has passed the major clinical test. It is a safe and well-tolerated vaccine, producing the strong virus-neutralising effect that we were hoping to see,” he said.

Andrew Nash, Chief Scientific Officer for CSL noted that this outcome highlights the risk of failure associated with early vaccine development, and the rigorous assessment involved in making decisions as to what discoveries advance.

Reacting to the announcement, Sanjaya Senanayake, a specialist in Infectious Diseases and Associate Professor of Medicine at The Australian National University, said while it is disappointing that an Australian vaccine candidate has been taken off the table, it is not surprising that one of the many COVID-19 vaccines has failed.

“In general, about 90 per cent of vaccines never make it to market. As a global community, we have been spoilt with the unprecedented swiftness and success with which the development of COVID-19 vaccines have taken place,” Senannayake said.

Diego Silva from Sydney Health Ethics in the University of Sydney School of Public Health noted that although the development might seem counter-intuitive, from a research ethics viewpoint, this is a success.

“Science cannot be all about producing positive results; negative results will and must occur. Negative results are also as important as success in science, since they, too, form part of the evidence base for future research,” said Silva.

“The researchers at UQ did the right thing by prioritising the safety of participants and the soundness of science by stopping when they did,” he added.

SHARE THIS ARTICLE ON
Close Story
QUICKREADS

Less time to read?

Try Quickreads

  • People rally in support of abortion rights Saturday, July 2, 2022, in Kansas City, Mo. (AP Photo/Charlie Riedel)

    Texas clinics halt abortions after state high court ruling

    The Friday night ruling stopped a three-day-old order by a Houston judge who said clinics could resume abortions up to six weeks into pregnancy. The following day, the American Civil Liberties Union said it doubted that any abortions were now being provided in a state of nearly 30 million people.

  • Other places from which Google will not store location data include fertility centers, addiction treatment facilities, and weight loss clinics.

    Google to delete user location history on US abortion clinic visits

    "If our systems identify that someone has visited one of these places, we will delete these entries from Location History soon after they visit," Jen Fitzpatrick, a senior vice president at Google, wrote in a blog post. "This change will take effect in the coming weeks."

  • Professor Ajay Agrawal, who was honoured with the Order of Canada in the 2022 list. (Credit: University of Toronto)

    Two Indo-Canadian academics honoured with Order of Canada

    Two Indo-Canadian academics, working on research to advance the betterment of mankind, have been honoured with one of the country's most prestigious awards, the Order of Canada. Their names were in the list published by the office of the governor-general of Canada Mary Simon. Both have been invested (as the bestowal of the awards is described) into the Order as a Member. They are professors Ajay Agrawal and Parminder Raina.

  • SpaceX founder and chief engineer Elon Musk.

    Elon Musk's Twitter hiatus, in 2nd week now,  generates curiosity 

    The world's richest person, Elon Musk, has not tweeted in about 10 days and it can't go unnoticed. The 51-year-old business tycoon has 100 million followers on the microblogging site, which he is planning to buy. Since April, he has been making headlines for the $44 billion deal and his comments and concerns about the presence of a large number of fake accounts on Twitter.

  • A Taliban fighter stands guard at a news conference about a new command of hijab by Taliban leader Mullah Haibatullah Akhundzada, in Kabul, Afghanistan.

    Taliban's reclusive supreme leader attends gathering in Kabul: Report

    The Taliban's reclusive supreme leader Haibatullah Akhundzada joined a large gathering of nationwide religious leaders in Kabul on Friday, the state news agency said, adding he would give a speech. The Taliban's state-run Bakhtar News Agency confirmed the reclusive leader, who is based in the southern city of Kandahar, was attending the meeting of more than 3,000 male participants from around the country, aimed at discussing issues of national unity.

SHARE
Story Saved
×
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Sunday, July 03, 2022